FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138042091> ?p ?o ?g. }

• W2138042091 endingPage "134" @default.
• W2138042091 startingPage "125" @default.
• W2138042091 abstract "Abstract Learning Objectives After completing this course, the reader will be able to: Cite the primary concerns of oncologists regarding influenza vaccination for their cancer patients.Describe research showing that cancer patients, whether taking myelosuppressive chemotherapy or not, are able to generate an immune response to the H1N1 vaccine similar to that of healthy controls. This article is available for continuing medical education credit at CME.TheOncologist.com Background. The immune response of patients who have cancer, who may be receiving immunosuppressive therapy, is generally considered to be decreased. This study aimed to evaluate the immune response of cancer patients to the 2009 influenza A (H1N1) vaccine. Patients and Methods. We conducted a prospective single site study comparing the immune response after H1N1 vaccination of healthy controls (group A), patients who had solid tumors and were taking myelosuppressive chemotherapy (group B), patients who had solid tumors and were taking nonmyelosuppressive or no treatment (group C), and patients who had hematologic malignancies (group D). Results. At 2–6 weeks after vaccination, seroconversion was observed in 80.0% of group A (95% confidence interval [CI], 65.0%–89.7%), 72.2% of group B (95% CI, 55.9%–84.3%), 87.0% of group C (95% CI, 72.2%–94.7%), and 75.0% of group D (95% CI, 52.8%–89.2%) (p = NS). The geometric mean titer ratio, that is, geometric mean factor increase in antibody titer after vaccination, was 12.6 (95% CI, 7.9–19.9), 12.7 (95% CI, 7.3–22.1), 23.0 (95% CI, 13.9–38.2), and 12.1 (95% CI, 5.3–27.9) (p = NS), and the seroprotection rates were 95.5% (95% CI, 84.0%–99.6%), 79.0% (95% CI, 63.4%–89.2%), 90.5% (95% CI, 77.4%–96.8%), and 90.0% (95% CI, 71%–98.7%) in the corresponding groups (p = NS). Immune responses were robust regardless of malignancy, or time intervals between the use of myelosuppressive or immunosuppressive medications and vaccination. No participants developed clinical H1N1 infection. Conclusion. Cancer patients, whether taking myelosuppressive chemotherapy or not, are able to generate an immune response to the H1N1 vaccine similar to that of healthy controls." @default.
• W2138042091 created "2016-06-24" @default.
• W2138042091 creator A5004143405 @default.
• W2138042091 creator A5006389719 @default.
• W2138042091 creator A5024834771 @default.
• W2138042091 creator A5026957643 @default.
• W2138042091 creator A5032658551 @default.
• W2138042091 creator A5036014755 @default.
• W2138042091 creator A5038488744 @default.
• W2138042091 creator A5039017612 @default.
• W2138042091 creator A5043213209 @default.
• W2138042091 creator A5056226298 @default.
• W2138042091 creator A5056868156 @default.
• W2138042091 creator A5079740640 @default.
• W2138042091 creator A5083732628 @default.
• W2138042091 creator A5083902994 @default.
• W2138042091 date "2012-01-01" @default.
• W2138042091 modified "2023-10-12" @default.
• W2138042091 title "Immunogenicity of an Inactivated Monovalent 2009 Influenza A (H1N1) Vaccine in Patients Who Have Cancer" @default.
• W2138042091 cites W1966623111 @default.
• W2138042091 cites W1970417480 @default.
• W2138042091 cites W1973128338 @default.
• W2138042091 cites W1974723087 @default.
• W2138042091 cites W1978332875 @default.
• W2138042091 cites W1980312663 @default.
• W2138042091 cites W1991508474 @default.
• W2138042091 cites W1995687578 @default.
• W2138042091 cites W1999211903 @default.
• W2138042091 cites W2001187841 @default.
• W2138042091 cites W2015015957 @default.
• W2138042091 cites W2016796034 @default.
• W2138042091 cites W2023278988 @default.
• W2138042091 cites W2046726344 @default.
• W2138042091 cites W2051402638 @default.
• W2138042091 cites W2053134839 @default.
• W2138042091 cites W2055978063 @default.
• W2138042091 cites W2058011797 @default.
• W2138042091 cites W2067216658 @default.
• W2138042091 cites W2068592034 @default.
• W2138042091 cites W2076982220 @default.
• W2138042091 cites W2079430155 @default.
• W2138042091 cites W2089902323 @default.
• W2138042091 cites W2111299679 @default.
• W2138042091 cites W2111360869 @default.
• W2138042091 cites W2114581239 @default.
• W2138042091 cites W2116095293 @default.
• W2138042091 cites W2123037109 @default.
• W2138042091 cites W2133205391 @default.
• W2138042091 cites W2133803922 @default.
• W2138042091 cites W2139400179 @default.
• W2138042091 cites W2142386470 @default.
• W2138042091 cites W2149026055 @default.
• W2138042091 cites W2149456801 @default.
• W2138042091 cites W2155467153 @default.
• W2138042091 cites W2170155793 @default.
• W2138042091 cites W2320628500 @default.
• W2138042091 cites W2409420104 @default.
• W2138042091 cites W2469390252 @default.
• W2138042091 cites W4239989216 @default.
• W2138042091 cites W61714529 @default.
• W2138042091 doi "https://doi.org/10.1634/theoncologist.2011-0220" @default.
• W2138042091 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3267811" @default.
• W2138042091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22240540" @default.
• W2138042091 hasPublicationYear "2012" @default.
• W2138042091 type Work @default.
• W2138042091 sameAs 2138042091 @default.
• W2138042091 citedByCount "16" @default.
• W2138042091 countsByYear W21380420912012 @default.
• W2138042091 countsByYear W21380420912013 @default.
• W2138042091 countsByYear W21380420912014 @default.
• W2138042091 countsByYear W21380420912015 @default.
• W2138042091 countsByYear W21380420912016 @default.
• W2138042091 countsByYear W21380420912017 @default.
• W2138042091 countsByYear W21380420912018 @default.
• W2138042091 countsByYear W21380420912019 @default.
• W2138042091 countsByYear W21380420912020 @default.
• W2138042091 countsByYear W21380420912022 @default.
• W2138042091 crossrefType "journal-article" @default.
• W2138042091 hasAuthorship W2138042091A5004143405 @default.
• W2138042091 hasAuthorship W2138042091A5006389719 @default.
• W2138042091 hasAuthorship W2138042091A5024834771 @default.
• W2138042091 hasAuthorship W2138042091A5026957643 @default.
• W2138042091 hasAuthorship W2138042091A5032658551 @default.
• W2138042091 hasAuthorship W2138042091A5036014755 @default.
• W2138042091 hasAuthorship W2138042091A5038488744 @default.
• W2138042091 hasAuthorship W2138042091A5039017612 @default.
• W2138042091 hasAuthorship W2138042091A5043213209 @default.
• W2138042091 hasAuthorship W2138042091A5056226298 @default.
• W2138042091 hasAuthorship W2138042091A5056868156 @default.
• W2138042091 hasAuthorship W2138042091A5079740640 @default.
• W2138042091 hasAuthorship W2138042091A5083732628 @default.
• W2138042091 hasAuthorship W2138042091A5083902994 @default.
• W2138042091 hasBestOaLocation W21380420911 @default.
• W2138042091 hasConcept C121608353 @default.
• W2138042091 hasConcept C126322002 @default.
• W2138042091 hasConcept C143998085 @default.
• W2138042091 hasConcept C159654299 @default.
• W2138042091 hasConcept C203014093 @default.

• next